TL;DR: Maven Bio’s AI Analyst can construct a full competitive landscape, research specific drugs or companies, or analyze trial data, all by leveraging our curated content library of over 10 million BioPharma documents. Join hundreds of users from the world's top BioPharma companies, consultancies, and venture capital firms and try our robust free tier at mavenbio.io
🎯 The Problem:
More than 90% of clinical-stage drugs fail - yet while scientific failures get most of the attention, ~20% of all programs actually fail for business and commercial reasons.
Why?
Today, therapeutic opportunities are evaluated using a highly manual process with fragmented information along with a heavy dose of consultants, hundreds of slides, and dozens of disparate data sources, which makes it difficult and time-consuming to assess the commercial potential of a drug.
✨ Our Solution:
Maven Bio’s AI Analyst for BioPharma Market Intelligence empowers teams to get smart on an opportunity area and understand the competitive landscape faster and more effectively.
Unlike a generative chatbot or traditional database that provides rows of data but takes no action, Maven Bio’s AI Research Analyst actually performs analysis for you, giving you meaningful insights on critical BioPharma business questions like:
In a field where accuracy is crucial, we leverage our proprietary content library of over 10 million BioPharma documents with a unique combination of both financial and scientific information, including drug and trial data, press releases, SEC filings, earnings transcripts, and much more to provide unrivaled breadth and depth.
👋 Our ask: How you can help
If you want to discuss additional customizations available in our Enterprise plan, or just want to chat, connect with us here.